Tempest Therapeutics, Inc.

Stage 4 · Declining · week 44

As of Oct 22, 2026, Tempest Therapeutics is in Stage 4, the downtrend phase, now in week 44 (since Dec 10, 2025). It closed at $0.52, 95.3% below its 52-week high and below its 200-day average, which is falling.

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. More about the company

$0.52

-5.95% today

$8.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is TPST early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 23w

S4 73w

S4 45w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 23w → S1 6w → S4 73w → S1 8w → S2 7w → S3 3w → S4 45w current

Total tracked: 166 weeks across 7 stage runs.

TPST among Biotechnology527th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…527	TPSTTempest Therapeutics, Inc.	Stage 4 · wk 44	5	−43.4%

vs 52W High

-95.3%

$0.52 lo$11.01 hi

95.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 44

1w13w26w

Week 44, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-66.8%

200 DMA: $1.57 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.06x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-43.4%

-43.6%

-71.0%

YTD

-82.3%

-95.0%

Scan Membership

Breakout Watch

Latest: 2023-04-20

3 appearances in last 60 days. First seen: 2019-03-26.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 44 · Vol 0.06x

2026-10-21S4

Wk 44 · Vol 0.11x

2026-10-20S4

Wk 44 · Vol 0.04x

2026-10-19S4

Wk 43 · Vol 0.04x

2026-10-16S4

Wk 43 · Vol 0.02x

2026-10-15S4

Wk 43 · Vol 0.04x

2026-10-14S4

Wk 43 · Vol 0.05x

2026-10-13S4

Wk 43 · Vol 0.07x

2026-10-12S4

Wk 42 · Vol 0.05x

2026-10-09S4

Wk 42 · Vol 0.06x

2026-10-08S4

Wk 42 · Vol 0.05x

2026-10-07S4

Wk 42 · Vol 0.09x

Moving averages & range

50 DMA

$0.89

200 DMA

$1.57

52W High

$11.01

52W Low

$0.52

5D Low

$0.52

Resistance levels (recent highs)

20d High

$0.83

60d High

$1.21

120d High

$2.15

250d High

$11.01

Next resistance

+59.8%

to 20d High

ROE

-931.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B -7.7

Tempest Therapeutics: quick answers

What stage is Tempest Therapeutics in?

As of Oct 22, 2026, Tempest Therapeutics (TPST) is in Stage 4, the downtrend phase. It entered Stage 4 on Dec 10, 2025 and is in week 44. What the four stages mean

Is Tempest Therapeutics in an uptrend?

No. Tempest Therapeutics is in a Stage 4 downtrend. It trades 66.8% below its 200-day average, which is falling.

How far is Tempest Therapeutics from its 52-week high?

Tempest Therapeutics closed at $0.52 on Oct 22, 2026, 95.3% below its 52-week high of $11.01. Its 52-week low is $0.52.

How has Tempest Therapeutics performed over the past year?

As of Oct 22, 2026, Tempest Therapeutics is down 95.0% over the past year and down 82.3% so far in 2026.

Which sector and industry is Tempest Therapeutics in?

Tempest Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.